Pro Medicus Ltd (ASX:PME)

Half Year 2025 Pro Medicus Ltd Earnings Call Transcript

Feb 12, 2025 / 12:00 AM GMT

Release Date Price: A$279.08 (-3.20%)

Transcript

Key Points

Positve

Pro Medicus Ltd (PMCUF) reported a record first half with revenue up 31.1% and profit after tax up 42.7%.
The company remains debt-free and has increased its cash and other investments by 17.7%.
Pro Medicus Ltd (PMCUF) has secured significant new contracts, including a $330 million deal with Trinity over 10 years.
The company has a strong pipeline of opportunities and continues to expand its footprint in various market segments.
Pro Medicus Ltd (PMCUF) is leveraging its R&D capabilities for next-generation products in cardiology and AI, positioning itself for future growth.

Negative

The company faces a highly competitive market, with some contracts lost to competitors primarily on price.
There is a global radiology workforce shortage, which could impact the company's ability to meet demand.
The transition to cloud-based solutions is ongoing, and some clients may be hesitant to adopt new technologies.
Pro Medicus Ltd (PMCUF) has a high exposure to the US dollar, which could pose currency risk.
The company's growth strategy requires continuous investment in R&D and resources, which could impact margins.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PME.AX - Pro Medicus Ltd
Half Year 2025 Pro Medicus Ltd Earnings Call
Feb 13, 2025 / 12:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to the Promedius Limited half year results briefing. All participants are in a listen-only mode. There'll be a presentation followed by a question and answer session. If you'd like to ask a question via the phones, you'll need to press the star key followed by the number one on your telephone keypad. If you'd like to ask a question via the webcast, please enter it into the Ask a question box and click submit. I would now like to hand the conference over to Doctor SAM Huppert, CEO. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.